FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs

Dr. Rachel Mendez MD, Medical Science Writer

✨ Why this is good news

Complicated urinary tract infections are serious bacterial infections that often require hospital treatment with IV antibiotics.

First oral carbapenem option.Before Utebzi, patients with complicated UTIs often needed IV antibiotics in a hospital. Now they can take an effective oral pill at home, avoiding hospital stays and reducing infection risk.
Targets drug resistant bacteria.Many complicated UTIs are caused by multidrug resistant pathogens that older oral antibiotics cannot treat. Utebzi is a carbapenem, a powerful class that still works against many resistant strains, offering a new lifeline.
Reduces treatment failure rates.Up to 34 percent of patients experience treatment failure with current options, leading to worse outcomes. This new drug provides a potent alternative that could lower that failure rate and prevent complications.
Helps over 3 million people yearly.Complicated UTIs affect millions in the U.S. each year, and many patients have limited oral choices. Utebzi expands access to effective treatment for a large population, especially those who cannot take IV therapy.

The U.S. Food and Drug Administration has approved Utebzi (tebipenem pivoxil), the first oral carbapenem antibiotic for adults with complicated urinary tract infections (cUTIs), including pyelonephritis. The decision offers a new option for patients who have limited or no alternative oral treatments, potentially reducing the need for hospital based intravenous care.

Complicated UTIs affect more than 3 million people in the United States each year, and treatment failure impacts up to 34 percent of patients. These infections are often caused by multidrug resistant pathogens and account for over $6 billion in annual healthcare costs. Carbapenems have long been the standard treatment for severe or resistant infections, but until now they were only available through intravenous administration, which requires hospitalization and reduces quality of life. The approval of Utebzi marks the first time an oral version of this powerful antibiotic class has been made available for these patients.

The approval is supported by the PIVOT-PO phase III trial, which compared oral tebipenem pivoxil to intravenous imipenem-cilastatin in hospitalized adults with cUTI. The oral drug achieved a 58.5 percent overall success rate compared to 60.2 percent for the IV treatment, meeting the criteria for non-inferiority. The safety profile was generally similar, with the most common side effects being diarrhea and headache, both mild or moderate and non-serious.

What This Means for Patients

For patients with complicated UTIs, the standard of care has often meant a hospital stay for IV antibiotics. An effective oral alternative could allow more treatment to occur in outpatient settings, reducing the burden on both patients and hospitals. Dr. Bilal Chughtai, Chief of Urology at Plainview Hospital, Northwell Health, called the approval a major milestone, noting that the current standard of care places a serious burden on patients and caregivers.

Utebzi is expected to be available to patients in the United States by the end of 2026. The drug was developed in collaboration with Spero Therapeutics and has received Qualified Infectious Disease Product and Fast Track designations from the FDA. As antibiotic resistance continues to rise, this new oral option represents a hopeful step toward more convenient and effective treatment for serious urinary tract infections.

This article is for informational purposes only and does not constitute medical advice. The information presented is based on published research and official announcements. Always consult a qualified healthcare professional before making any medical decisions.